VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (“VBI”) today announced the voting results from its annual general and special meeting (the “Meeting”) held on September 23, 2016.
A total of 26,558,396 shares were represented at the Meeting, being 73.50% of the Company’s issued and outstanding common shares. The shareholders voted on and approved all matters brought before the Meeting, including the appointment of EisnerAmper LLP, Chartered Accountants as auditors of the Company and to authorize the directors to fix their remuneration, the election of the directors of the Company, and an advisory resolution to approve the Company’s approach to executive compensation.
Detailed results of the vote for the election of directors are provided below:
| Votes For | Votes Withheld | |||
| Nominee | # | % | # | % |
| Election of Directors | ||||
| Jeff Baxter | 18,066,460 | 99.71% | 52,985 | 0.29% |
| Steven Gillis | 18,118,302 | 99.99% | 1,143 | 0.01% |
| Scott Requadt | 18,116,772 | 99.99% | 2,673 | 0.01% |
| Michel De Wilde | 18,116,389 | 99.98% | 3,056 | 0.02% |
| Sam Chawla | 18,117,972 | 99.99% | 1,473 | 0.01% |
| Steven D. Rubin | 18,017,032 | 99.43% | 102,413 | 0.57% |
| Adam Logal | 18,112,942 | 99.96% | 6,503 | 0.04% |
The Company is also pleased to announce that the Chief Financial Officer of VBI Vaccines Inc. (Delaware) prior to the merger (the “Merger”) of the Company (then SciVac Therapeutics Inc.) and VBI Vaccines Inc. (Delaware), Egidio Nascimento, has been named Chief Financial Officer of the Company. The Company would like to thank James J. Martin for his role as Chief Financial Officer of the Company during the Company’s transition period post-Merger.
